LivaNova posts Q3 2026 earnings beat and lifts full‑year revenue and EPS guidance
LivaNova reported third‑quarter 2026 revenue of $393.1 million, up 9.9% year‑over‑year, and adjusted diluted EPS of $1.23, beating estimates. GAAP diluted EPS was $0.11. The company raised its full‑year 2026 revenue growth outlook to 9‑10% (constant‑currency) and adjusted EPS guidance to $4.40‑$4.50. Management highlighted a new oxygenator manufacturing line, new CPT codes for sleep‑apnea therapy, and strong demand across cardiopulmonary and neuromodulation segments.
Why it matters
The raised guidance suggests higher future cash flow and earnings than previously expected, which could support a higher valuation for LIVN (the company’s own press release says the updated outlook reflects confidence across the portfolio). Analysts such as Jefferies have responded by increasing their price target to $120, indicating market optimism.
Key facts
- 1Third‑quarter revenue was $393.1 million, a 9.9% increase on a reported basis and 10.0% on a constant‑currency basis versus the prior year. sec.gov
- 2Adjusted diluted earnings per share for the quarter were $1.23, while GAAP diluted EPS was $0.11. sec.gov
- 3Full‑year 2026 revenue growth guidance was raised to a range of 9%‑10% on a constant‑currency basis. sec.gov
- 4Full‑year 2026 adjusted diluted EPS guidance was raised to $4.40‑$4.50. sec.gov
- 5The company launched a dedicated oxygenator manufacturing line, marking a production milestone. sec.gov
- 6New Category I CPT codes for LivaNova’s proximal hypoglossal nerve stimulation therapy were announced, effective Jan 1 2028. sec.gov
Summary written by AlphAI AI Desk from 17 of 17 sources. Not investment advice. Figures are as stated by the linked sources.